A common 5′-UTR variant in MATE2-K is associated with poor response to metformin

Clinical Pharmacology and Therapeutics

Volumn 90, Issue 5, 2011, Pages 674-684

  Choi, J H ^a   Yee, S W ^b   Ramirez, A H ^c   Morrissey, K M ^b   Jang, G H ^a   Joski, P J ^d   Mefford, J A ^e   Hesselson, S E ^b   Schlessinger, A ^b,f   Jenkins, G ^b   Castro, R A ^b   Johns, S J ^b   Stryke, D ^b   Sali, A ^b,f   Ferrin, T E ^b   Witte, J S ^e   Kwok, P Y ^b   Roden, D M ^g   Wilke, R A ^c   McCarty, C A ^h   Davis, R L ^d   Giacomini, K M ^b   more..

^a Ewha Womans University   (South Korea)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c VANDERBILT UNIVERSITY MEDICAL CENTER   (United States)

^d KAISER PERMANENTE   (United States)

^e UNIVERSITY OF CALIFORNIA   (United States)

^f UNIVERSITY OF CALIFORNIA   (United States)

^g VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

^h MARSHFIELD CLINIC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

HEMOGLOBIN A1C; METFORMIN; MULTIDRUG AND TOXIN EXTRUSION 2; MYELOID ZINC FINGER 1; ORGANIC CATION TRANSPORTER; UNCLASSIFIED DRUG; ZINC FINGER PROTEIN; ANTIDIABETIC AGENT; GLYCOSYLATED HEMOGLOBIN; LUCIFERASE; MATE2 K PROTEIN, HUMAN; MATE2-K PROTEIN, HUMAN;

ADULT; DRUG RESPONSE; DRUG UPTAKE; FEMALE; GENE FREQUENCY; GENE LINKAGE DISEQUILIBRIUM; GENE STRUCTURE; GENETIC ASSOCIATION; GENETIC POLYMORPHISM; GENETIC VARIABILITY; HAPLOTYPE; HOMOZYGOSITY; HUMAN; HUMAN CELL; MAJOR CLINICAL STUDY; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVIEW; AGED; ALLELE; ANIMAL; ARTICLE; CELL STRAIN; CELL STRAIN HCT116; CELL STRAIN HEK293; GENETICS; METABOLISM; MIDDLE AGED; PROMOTER REGION; RACE; RETROSPECTIVE STUDY; SWINE; TREATMENT OUTCOME;

ADULT; AGED; ALLELES; ANIMALS; CONTINENTAL POPULATION GROUPS; DIABETES MELLITUS, TYPE 2; FEMALE; GENETIC VARIATION; HAPLOTYPES; HCT116 CELLS; HEK293 CELLS; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; HYPOGLYCEMIC AGENTS; LLC-PK1 CELLS; LUCIFERASES; MALE; METFORMIN; MIDDLE AGED; ORGANIC CATION TRANSPORT PROTEINS; POLYMORPHISM, GENETIC; PROMOTER REGIONS, GENETIC; RETROSPECTIVE STUDIES; SWINE; TREATMENT OUTCOME;

EID: 80054970528     PISSN: 00099236     EISSN: 15326535     Source Type: Journal    
DOI: 10.1038/clpt.2011.165     Document Type: Review

References (47)

1. Fujita, T., Urban, T.J., Leabman, M.K., Fujita, K. & Giacomini, K.M. Transport of drugs in the kidney by the human organic cation transporter, OCT2 and its genetic variants. J. Pharm. Sci. 95, 25-36 (2006).
2. Otsuka, M., Matsumoto, T., Morimoto, R., Arioka, S., Omote, H. & Moriyama, Y. A human transporter protein that mediates the final excretion step for toxic organic cations. Proc. Natl. Acad. Sci. USA 102, 17923-17928 (2005). (Pubitemid 41798478)
3. Masuda, S. et al. Identification and functional characterization of a new human kidney-specific H+/organic cation antiporter, kidney-specific multidrug and toxin extrusion 2. J. Am. Soc. Nephrol. 17, 2127-2135 (2006). (Pubitemid 44141902)
4. Tanihara, Y., Masuda, S., Sato, T., Katsura, T., Ogawa, O. & Inui, K. Substrate specificity of MATE1 and MATE2-K, human multidrug and toxin extrusions/H(+)-organic cation antiporters. Biochem. Pharmacol. 74, 359-371 (2007). (Pubitemid 46890818)
5. Watanabe, S., Tsuda, M., Terada, T., Katsura, T. & Inui, K. Reduced renal clearance of a zwitterionic substrate cephalexin in MATE1-deficient mice. J. Pharmacol. Exp. Ther. 334, 651-656 (2010).
6. Tsuda, M., Terada, T., Mizuno, T., Katsura, T., Shimakura, J. & Inui, K. Targeted disruption of the multidrug and toxin extrusion 1 (mate1) gene in mice reduces renal secretion of metformin. Mol. Pharmacol. 75, 1280-1286 (2009).
7. Chen, Y. et al. Genetic variants in multidrug and toxic compound extrusion-1, hMATE1, alter transport function. Pharmacogenomics J. 9, 127-136 (2009).
8. Choi, J.H. et al. Identification and characterization of novel polymorphisms in the basal promoter of the human transporter, MATE1. Pharmacogenet Genomics 19, 770-780 (2009).
9. Kajiwara, M. et al. Identification of multidrug and toxin extrusion (MATE1 and MATE2-K) variants with complete loss of transport activity. J. Hum. Genet. 54, 40-46 (2009).
10. Meyer zu Schwabedissen, H.E., Verstuyft, C., Kroemer, H.K., Becquemont, L. & Kim, R.B. Human multidrug and toxin extrusion 1 (MATE1/SLC47A1) transporter: functional characterization, interaction with OCT2 (SLC22A2), and single nucleotide polymorphisms. Am. J. Physiol. Renal Physiol. 298, F997-F1005 (2010).
11. Becker, M.L., Visser, L.E., van Schaik, R.H., Hofman, A., Uitterlinden, A.G. & Stricker, B.H. Genetic variation in the organic cation transporter 1 is associated with metformin response in patients with diabetes mellitus. Pharmacogenomics J. 9, 242-247 (2009).
12. Jablonski, K.A. et al. Common variants in 40 genes assessed for diabetes incidence and response to metformin and lifestyle intervention in the diabetes prevention program. Diabetes 59, 2672-2681 (2010).
13. Komatsu, T. et al. Characterization of the human MATE2 proton-coupled polyspecific organic cation exporter. Int. J. Biochem. Cell Biol. 43, 913-918 (2011).
14. Zhou, K. et al. Reduced-function SLC22A1 polymorphisms encoding organic cation transporter 1 and glycemic response to metformin: a GoDARTS study. Diabetes 58, 1434-1439 (2009).
15. Becker, M.L., Visser, L.E., van Schaik, R.H., Hofman, A., Uitterlinden, A.G. & Stricker, B.H. Genetic variation in the multidrug and toxin extrusion 1 transporter protein influences the glucose-lowering effect of metformin in patients with diabetes: a preliminary study. Diabetes 58, 745-749 (2009).
16. Tzvetkov, M.V. et al. The effects of genetic polymorphisms in the organic cation transporters OCT1, OCT2, and OCT3 on the renal clearance of metformin. Clin. Pharmacol. Ther. 86, 299-306 (2009).
17. Shu, Y. et al. Effect of genetic variation in the organic cation transporter 1 (OCT1) on metformin action. J. Clin. Invest. 117, 1422-1431 (2007). (Pubitemid 46718430)
18. Shu, Y. et al. Effect of genetic variation in the organic cation transporter 1, OCT1, on metformin pharmacokinetics. Clin. Pharmacol. Ther. 83, 273-280 (2008).
19. He, X. et al. Structure of a cation-bound multidrug and toxic compound extrusion transporter. Nature 467, 991-994 (2010).
20. Noll, L., Peterson, F.C., Hayes, P.L., Volkman, B.F. & Sander, T. Heterodimer formation of the myeloid zinc finger 1 SCAN domain and association with promyelocytic leukemia nuclear bodies. Leuk. Res. 32, 1582-1592 (2008).
21. Lenny, N., Westendorf, J.J. & Hiebert, S.W. Transcriptional regulation during myelopoiesis. Mol. Biol. Rep. 24, 157-168 (1997). (Pubitemid 27358369)
22. Saji, T., Kikuchi, R., Kusuhara, H., Kim, I., Gonzalez, F.J. & Sugiyama, Y. Transcriptional regulation of human and mouse organic anion transporter 1 by hepatocyte nuclear factor 1 alpha/beta. J. Pharmacol. Exp. Ther. 324, 784-790 (2008). (Pubitemid 351185851)
23. Manna, S.K., Mukhopadhyay, A. & Aggarwal, B.B. IFN-alpha suppresses activation of nuclear transcription factors NF-kappa B and activator protein 1 and potentiates TNF-induced apoptosis. J. Immunol. 165, 4927-4934 (2000).
24. Chen, Y. et al. Effect of genetic variation in the organic cation transporter 2 on the renal elimination of metformin. Pharmacogenet. Genomics 19, 497-504 (2009).
25. Becker, M.L., Visser, L.E., van Schaik, R.H., Hofman, A., Uitterlinden, A.G. & Stricker, B.H. Genetic variation in the multidrug and toxin extrusion 1 transporter protein influences the glucose-lowering effect of metformin in patients with diabetes: a preliminary study. Diabetes 58, 745-749 (2009).
26. 1000 Genomes Project Consortium. A map of human genome variation from population-scale sequencing. Nature 467, 1061-1073 (2010).
27. Morris, J.F. et al. The myeloid zinc finger gene, MZF-1, regulates the CD34 promoter in vitro. Blood 86, 3640-3647 (1995).
28. Hromas, R. et al. Hematopoietic transcriptional regulation by the myeloid zinc finger gene, MZF-1. Curr. Top. Microbiol. Immunol. 211, 159-164 (1996). (Pubitemid 26019276)
29. Wang, Z.J., Yin, O.Q., Tomlinson, B. & Chow, M.S. OCT2 polymorphisms and in-vivo renal functional consequence: studies with metformin and cimetidine. Pharmacogenet. Genomics 18, 637-645 (2008).
30. Song, I.S. et al. Genetic variants of the organic cation transporter 2 influence the disposition of metformin. Clin. Pharmacol. Ther. 84, 559-562 (2008).
31. Toyama, K. et al. Heterozygous variants of multidrug and toxin extrusions (MATE1 and MATE2-K) have little influence on the disposition of metformin in diabetic patients. Pharmacogenet. Genomics 20, 135-138 (2010).
32. The GoDARTS and UKPDS Diabetes Pharmacogenetics Study Group et al. Common variants near ATM are associated with glycemic response to metformin in type 2 diabetes. Nat. Genet. 43, 117-120 (2011).
33. Roden, D.M. & Tyndale, R.F. Pharmacogenomics at the tipping point: challenges and opportunities. Clin. Pharmacol. Ther. 89, 323-327 (2011).
34. Chen, Y., Zhang, S., Sorani, M. & Giacomini, K.M. Transport of paraquat by human organic cation transporters and multidrug and toxic compound extrusion family. J. Pharmacol. Exp. Ther. 322, 695-700 (2007). (Pubitemid 47105798)
35. Yee, S.W. et al. Identification and characterization of proximal promoter polymorphisms in the human concentrative nucleoside transporter 2 (SLC28A2). J. Pharmacol. Exp. Ther. 328, 699-707 (2009).
36. Urban, T.J. et al. Functional effects of protein sequence polymorphisms in the organic cation/ergothioneine transporter OCTN1 (SLC22A4). Pharmacogenet Genomics 17, 773-782 (2007). (Pubitemid 47263072)
37. Chen, L. et al. Role of organic cation transporter 3 (SLC22A3) and its missense variants in the pharmacologic action of metformin. Pharmacogenet. Genomics 20, 687-699 (2010).
38. Shima, J.E. et al. Genetic variants of human organic anion transporter 4 demonstrate altered transport of endogenous substrates. Am. J. Physiol. Renal Physiol. 299, F767-F775 (2010).
39. Xu, J., Wu, Y., He, L., Yang, Y., Moore, S.A. & Hsu, C.Y. Regulation of cytokineinduced iNOS expression by a hairpin oligonucleotide in murine cerebral endothelial cells. Biochem. Biophys. Res. Commun. 235, 394-397 (1997). (Pubitemid 27313718)
40. Sali, A. & Blundell, T.L. Comparative protein modelling by satisfaction of spatial restraints. J. Mol. Biol. 234, 779-815 (1993). (Pubitemid 24007801)
41. McCarty, C.A. & Wilke, R.A. Biobanking and pharmacogenomics. Pharmacogenomics 11, 637-641 (2010).
42. Platt, R. et al. Multicenter epidemiologic and health services research on therapeutics in the HMO Research Network Center for Education and Research on Therapeutics. Pharmacoepidemiol. Drug Saf. 10, 373-377 (2001). (Pubitemid 33138456)
43. Pendergrass, S., Dudek, S.M., Roden, D.M., Crawford, D.C. & Ritchie, M.D. Visual integration of results from a large DNA biobank (biovu) using synthesis-view. Pac. Symp. Biocomput. 265-275 (2011).
44. Ritchie, M.D. et al. Robust replication of genotype-phenotype associations across multiple diseases in an electronic medical record. Am. J. Hum. Genet. 86, 560-572 (2010).
45. Wilke, R.A. et al. The emerging role of electronic medical records in pharmacogenomics. Clin. Pharmacol. Ther. 89, 379-386 (2011).
46. Roden, D.M. et al. Development of a large-scale de-identified DNA biobank to enable personalized medicine. Clin. Pharmacol. Ther. 84, 362-369 (2008).
47. Levey, A.S. et al. Using standardized serum creatinine values in the modification of diet in renal disease study equation for estimating glomerular filtration rate. Ann. Intern. Med. 145, 247-254 (2006). (Pubitemid 46768608)